DOI : 10.1055/s-00000034

Klinische Pädiatrie

Issue 03 · Volume 225 · May 2013 DOI: 10.1055/s-003-25016


XXVI. Jahrestagung der Kind-Philipp-Stiftung für Leukämieforschung
Wilsede, Lüneburger Heide, 5.–8. Juni 2013

Wissenschaftliche Leitung: Prof. Dr. Martin Horstmann, Prof. Dr. Rolf Marschalek, Prof. Dr. Martin Stanulla
Abstracts (HTML) List of Authors
A23
Geyer, A; Pütz, G; Reichardt, W; Süss, R; Kontny, U: Imaged-guided Therapy of Ewing Sarcoma Using Magnetic Nanoparticles Coupled with anti-CD99-Antibody and siRNA against EWS/FLI1
A24
Krämer, A; Ackermann, S; Roels, F; Kocak, H; Hertwig, F; Kahlert, Y; Engesser, A; Sherkheli, F; Peifer, M; Thomas, R; Fischer, M: Functional characterization of somatically mutated genes in neuroblastoma
A25
Sterz, C; Oberthuer, A; Juraeva, D; Schmidt, R; Faldum, A; Berthold, F; Hero, B; Brors, B; Fischer, M: A novel treatment stratification system for current low- and intermediate-risk neuroblastoma patients using gene expression-based classification
A26
Eger, C; Brackrock, D; Siebert, N; Lode, HN: Generation and characterization of ganglidiximab for active immunotherapy of neuroblastoma
A27
Sherkheli, F; Ackermann, S; Roels, F; Kocak, H; Volland, R; Thomas, R; Fischer, M: The transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastoma cells
A28
Wiegand, I; Milde, T; Deubzer, HE; Balasubramanian, S; Witt, O; Oehme, I: Selective inhibition of Histone Deacetylase 8 as a novel therapeutic strategy for the treatment of high-risk neuroblastoma
A29
Fabian, J; Lodrini, M; Schier, MC; Thole, T; Kopp-Schneider, A; Capper, D; Deimling, A von; Oehme, I; Wiegand, I; Milde, T; Roels, F; Fischer, M; Kulozik, AE; Witt, O; Deubzer, HE: GRHL1 inhibits tumorigenicity and is a prognostic marker in neuroblastoma
A30
Ecker, J; Oehme, I; Schomburg, A; Mazitschek, R; Korshunov, A; Kool, M; Deubzer, HE; Deimling, A von; Kulozik, AE; Pfister, S; Witt, O; Milde, T: Dysregulated expression of histone deacetylases in medulloblastoma – potential targets for selective inhibitor treatment
A31
Gessi, M; Büren, A von; Treitzl, A; zur Mühlen, A; Rutkowski, S; Pietsch, T: MYCN amplification predicts poor outcome of patients with LIN28 negative supratentorial primitive neuroectodermal tumors of the central nervous system (CNS-PNET)
A32
Goschzik, T; zur Mühlen, A; Kristiansen, G; Pietsch, T: Molecular stratification of medulloblastoma: Comparison of histological and genetical methods to detect Wnt activated tumors